IMMU - Immunomedics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
14.06
-0.11 (-0.78%)
At close: 4:00PM EDT

14.49 +0.43 (3.06%)
Pre-Market: 4:43AM EDT

Stock chart is not supported by your current browser
Previous Close14.17
Open14.15
Bid13.56 x 900
Ask14.49 x 4000
Day's Range13.93 - 14.45
52 Week Range11.55 - 24.99
Volume1,064,812
Avg. Volume2,212,321
Market Cap2.699B
Beta (3Y Monthly)1.63
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • ACCESSWIRE

    SHAREHOLDER REMINDER: Immunomedics, Inc. (IMMU) Sued for Misleading Shareholders; The Law Offices of Timothy L. Miles Encourages Immunomedics Shareholders to Contact the Firm

    HENDERSONVILLE, TN / ACCESSWIRE / October 9, 2019 / The Law Offices of Timothy L. Miles, who has been leading the fight to protect shareholder rights for over 18 years, reminds shareholders that purchasers ...

  • GlobeNewswire

    Bragar Eagel & Squire is Investigating Certain Officers and Directors of Healthcare Services Group, Heron Therapeutics, Immunomedics, and Karyopharm and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire is investigating certain officers and directors of Healthcare Services Group, In. Bragar Eagel & Squire is investigating certain officers and directors of Healthcare Services Group, Inc. following a class action complaint that was filed against Healthcare Services on March 22, 2019.

  • GlobeNewswire

    Immunomedics to Present at the 2019 Cantor Global Healthcare Conference  

    Immunomedics, Inc. (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to present at the 2019 Cantor Global Healthcare Conference on Friday, October 4, 2019 at 10:05 a.m. Eastern Time in New York, N.Y. A live audio webcast of the presentation will be accessible from the Company’s website at https://immunomedics.com/investors/. The Company will also participate in one-on-one meetings with institutional investors at the conference.

  • GlobeNewswire

    Immunomedics Provides Corporate Update

    Immunomedics, Inc. (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today presented at the European Society for Medical Oncology (ESMO) Annual Congress interim data from the 100-patient cohort of cisplatin-eligible patients of the Company’s TROPHY-U-01 open-label Phase 2 study. In this interim report, sacituzumab govitecan produced an overall response rate (ORR) of 29 percent in 35 patients with metastatic urothelial cancer (mUC) who have relapsed or are refractory to immune checkpoint inhibitors (CPI) and platinum-based chemotherapy.

  • ACCESSWIRE

    SHAREHOLDER ALERT: Immunomedics, Inc. (IMMU) Sued for Misleading Shareholders; The Law Offices of Timothy L. Miles Encourages Immunomedics Shareholders to Contact the Firm

    HENDERSONVILLE, TN / ACCESSWIRE / September 16, 2019 / The Law Offices of Timothy L. Miles, who has been leading the fight to protect shareholder rights for over 18 years, announces that purchasers of ...

  • GlobeNewswire

    Immunomedics to Host Investor Event and Webcast on September 28, 2019 During ESMO Congress

    Immunomedics, Inc. (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host an Investor Event on Saturday, September 28, 2019 at 6:30 p.m. Central European Summer Time in Barcelona, Spain, during the Congress 2019. The event will feature presentations by key opinion leaders including Scott Tagawa, M.D., MS, Richard A. Stratton Associate Professor in Hematology & Oncology, Associate Professor of Medicine & Urology, Weill Cornell Medicine, and Associate Attending Physician, NewYork-Presbyterian – Weill Cornell Medical Center, who will present the interim results from TROPHY-U-01 at the Congress. Cora N. Sternberg, M.D., FACP, Clinical Director, Englander Institute for Precision Medicine and Professor of Medicine in Hematology & Oncology, Weill Cornell Medicine and NewYork-Presbyterian will discuss the implications of these data in an evolving metastatic urothelial cancer landscape.

  • GlobeNewswire

    Bragar Eagel & Squire is Investigating Certain Officers and Directors of MGT Capital Investments, First American Financial, Immunomedics, and AAC Holdings and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire is investigating certain officers and directors of MGT Capital Investments (Other OTC: MGTI), First American Financial Corporation (FAF), Immunomedics, Inc. (IMMU), and AAC Holdings, Inc. (AAC) on behalf of long-term stockholders. Bragar Eagel and Squire is investigating certain officers and directors of MGT Capital Investments following a class action complaint that was filed against MGT Capital on October 9, 2018. The complaint alleges that throughout the class period, defendants made materially false and misleading statements regarding the company's business, operational and compliance policies.

  • GlobeNewswire

    Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Metastatic Urothelial Cancer at ESMO 2019 Annual Congress

    Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that its TROPHY-U-01 late-breaking abstract on interim results of sacituzumab govitecan in patients with metastatic urothelial cancer (mUC) has been selected for oral presentation at the ESMO 2019 Annual Congress, taking place from  September 27 to October 1, 2019, at the Fira Barcelona, Spain. “We look forward to presenting, for the first time, interim data for sacituzumab govitecan in metastatic urothelial cancer patients who are relapsed or refractory to platinum-based and checkpoint inhibitor therapies,” commented Dr. Behzad Aghazadeh, Executive Chairman.

  • Business Wire

    Shareholder Alert: Robbins Arroyo LLP Reminds Investors Immunomedics, Inc. (IMMU) Sued for Misleading Shareholders

    Shareholder rights law firm Robbins Arroyo LLP reminds investors that purchasers of Immunomedics, Inc. filed a class action complaint against the company for alleged violations of the Securities Exchange Act of 1934 between August 23, 2018 and December 20, 2018.

  • GlobeNewswire

    Immunomedics to Participate in Upcoming Healthcare Conferences

    Live audio webcast of the fireside chats will be accessible from the Company’s website at https://immunomedics.com/investors/. The Company will also participate in one-on-one meetings with institutional investors at these conferences.

  • GlobeNewswire

    Immunomedics Reports Second Quarter 2019 Results and Provides Corporate Update

    ASCENT Study Reached Target Patient Enrollment First Patients Dosed in TROPICS-02 Study in HR+/HER2– Metastatic Breast Cancer Trop-2-Enriched TROPICS-03 Basket Study Initiated.

  • GlobeNewswire

    Immunomedics to Report Second Quarter 2019 Results and Host Conference Call and Webcast on August 7, 2019

    Immunomedics, Inc. (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Wednesday, August 7, 2019 at 5:00 p.m. Eastern Time to discuss financial results for the second quarter of 2019 and provide a corporate update. The conference call will be webcast via the Investors page on the Company’s website at https://immunomedics.com/investors/. Approximately two hours following the live event, a webcast replay of the conference call will be available on the Company’s website for approximately 30 days.

  • GlobeNewswire

    Immunomedics Reports First Quarter 2019 Results and Provides Corporate Update

    Agreement with Janssen Established to Co-Promote Balversa Sacituzumab Govitecan Licensed to Everest Medicines for Greater China and Certain Asian Countries Resubmission of.

  • GlobeNewswire

    Immunomedics To Participate In Upcoming Healthcare Conferences

    Live audio webcast of the fireside chats will be accessible from the Company’s website at https://immunomedics.com/investors/. The Company will also participate in one-on-one meetings with institutional investors at these conferences.

  • GlobeNewswire

    Immunomedics to Report First Quarter 2019 Results and Host Conference Call and Webcast on May 9, 2019

    Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Thursday, May 9, 2019 at 8:00 a.m. Eastern Time to discuss financial results for the first quarter of 2019 and provide a corporate update. The conference call will be webcast via the Investors page on the Company’s website at https://immunomedics.com/investors/. Approximately two hours following the live event, a webcast replay of the conference call will be available on the Company’s website for approximately 30 days.

  • GlobeNewswire

    Immunomedics and Everest Medicines Announce Exclusive License Agreement for Sacituzumab Govitecan in East and Southeast Asia Excluding Japan

    Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC) and Everest Medicines II Limited (“Everest Medicines”), a C-Bridge Capital-backed biopharmaceutical company, today announced an exclusive license agreement to  develop, register, and commercialize sacituzumab govitecan in Greater China, South Korea and certain Southeast Asian countries (Territory). “We are pleased to be partnering with Everest Medicines to commercialize sacituzumab govitecan in the Asian market outside Japan and further develop the product in solid tumor indications of high unmet need in the territory,” said Usama Malik, Chief Financial Officer and Chief Business Officer of Immunomedics.

  • GlobeNewswire

    Immunomedics Announces Departure of Chief Medical Officer

    “I am proud to have been part of Immunomedics and have full confidence in the capabilities of the team to bring sacituzumab govitecan to patients in a timely manner and help patients with difficult-to-treat cancers across the U.S. and the world. My decision comes after careful consideration and is driven by my personal priorities and a desire to be close to my family after many years of having worked far away from home,” commented Dr. Rob Iannone. Behzad Aghazadeh, Executive Chairman of Immunomedics, commented, “We thank Rob for his service to the Company, and wish him well in his new endeavors.

  • GlobeNewswire

    Immunomedics Announces Promotion Agreement With Janssen for Erdafitinib in the U.S.

    Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it has entered into a promotion agreement in which Immunomedics will provide detailing services  to Janssen Biotech Inc. (Janssen), for erdafitinib in the U.S. “We are delighted to be collaborating with Janssen and we look forward to working closely with the Janssen team to help promote erdafitinib," said Brendan Delaney, Chief Commercial Officer of Immunomedics.

  • GlobeNewswire

    Immunomedics Appoints Barbara G. Duncan to Board of Directors

    Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the appointment of Barbara G. Duncan to the Company’s Board of Directors and as the Chairperson of the Audit Committee. Ms. Duncan has over 30 years of financial leadership experience, of which 17 are in the life sciences industry. “We are honored to have Barbara join our Board.

  • GlobeNewswire

    Immunomedics to Participate in Cowen and Company 39th Annual Health Care Conference

    Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the Company will participate in a fireside chat at Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019 at 2:10 p.m. Eastern Time at the Boston Marriott Copley Place, Boston, MA. A live audio webcast of the presentation will be accessible from the Company’s website at https://immunomedics.com/investors/. The Company will also participate in one-on-one meetings with institutional investors at the conference.

  • GlobeNewswire

    Research Report Identifies Axalta Coating, The Home Depot, Immunomedics, Kosmos Energy, Casa, and Ormat Technologies with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, March 01, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • GlobeNewswire

    Lawsuit for Investors in NASDAQ: IMMU shares against Immunomedics, Inc. announced by Shareholders Foundation

    SAN DIEGO, Feb. 26, 2019 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: IMMU shares over alleged securities laws.

  • GlobeNewswire

    CLASS ACTION UPDATE for IMMU, ALKS and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, Feb. 25, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..